DaVita Inc. Reports 6% Revenue Growth to $3.42 Billion in Q1 2026

DaVita Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of $3.42 billion, a 6% increase from $3.22 billion in the same period last year. The company's net income attributable to DaVita Inc. rose to $197.53 million, or $2.93 per share, compared to $162.92 million, or $2.05 per share, in the first quarter of 2025. This performance reflects a 21% increase in net income year-over-year, driven by higher dialysis patient service revenues, which reached $3.27 billion, up from $3.10 billion in the prior year.

In terms of operational metrics, DaVita's U.S. dialysis business experienced a slight decline in treatment volumes, with 7.03 million dialysis treatments reported, a decrease of 0.2% compared to the same quarter last year. However, the average patient service revenue per treatment increased to $417.59, up 4.4% from $400.14 in the previous year. The company also noted a stable patient count, which contributed to the overall revenue growth despite the slight dip in treatment volumes.

Strategically, DaVita has been active in expanding its services and capabilities. The company signed a definitive agreement to acquire a noncontrolling minority interest in Elara Caring, a provider of home health and hospice services, for approximately $200 million, with the transaction expected to close mid-year 2026. This acquisition aligns with DaVita's strategy to enhance its integrated kidney care offerings and expand its service portfolio.

On the operational front, DaVita's employee headcount as of March 31, 2026, was approximately 66,185, reflecting a slight decrease from the previous year. The company continues to focus on improving operational efficiencies, which have helped mitigate rising labor costs. Additionally, DaVita's cash flow from operating activities increased to $321 million, up from $180 million in the same quarter last year, indicating improved liquidity and operational performance.

Looking ahead, DaVita remains optimistic about its growth prospects, despite ongoing challenges in the healthcare landscape, including regulatory changes and competitive pressures. The company anticipates continued revenue growth driven by its integrated kidney care initiatives and strategic acquisitions. However, it acknowledges potential risks related to market conditions, labor costs, and regulatory changes that could impact its operations and financial performance in the future.